Table 3.
Unadjusted and Adjusted Regression Coefficient Estimates and 95% Confidence Intervals (CI) that Explain the mini-OQLQ for Patients With Incident Fractures Versus Those Without Incident Fracturesa.
| Mini-OQLQ | Vertebral Fracture Group (I) | Non-Vertebral Fracture Group (II) | ||||||
| Domains | Estimates Unadjusted CI | (n) | Adjusted Estimates CI | (n) | Unadjusted Estimates CI | (n) | Adjusted Estimates CI | (n) |
| Total Score | -0.77 | (699) | -0.86 | (673) | -0.38 | (737) | -0.47 | (711) |
| -1.22, -0.31 | -1.30, -0.43 | -0.62, -0.13 | -0.70, -0.25 | |||||
| Symptoms | -0.70 | (1755) | -0.76 | (1214) | -0.17 | (1847) | -0.25 | (1295) |
| -1.12, -0.29 | -1.23, -0.30 | -0.41, 0.07c | -0.49, -0.01 | |||||
| Physical Functioning | -0.76 | (1226) | -1.12 | (1113) | -0.35 | (1294) | -0.39 | (1181) |
| -1.20, -0.32 | -1.57, -0.67 | -0.62, -0.09 | -0.65, -0.14 | |||||
| Emotional Functioning | -0.46 | (1756) | -1.06 | (1581) | -0.90 | (1850) | -0.97 | (1669) |
| -0.85, -0.07 | -1.44, -0.68 | -1.13, -0.66 | -1.20, -0.75 | |||||
| Activities of Daily Living | -1.13 | (1290) | -1.47 | (1116) | -0.41 | (1365) | -0.47 | (1188) |
| -1.63, -0.63 | -1.97, -0.96 | -0.69, -0.14 | -0.73, -0.21 | |||||
| Leisure | -0.81 | (1038) | -0.92 | (991) | 0.08 | (1087) | -0.05 | (953) |
| -1.29, -0.32 | -1.37, -0.47 | -0.22, 0.37c | -0.32, 0.23c | |||||
aRegression coefficient estimates and 95% CI were calculated based on differences between the incident vertebral and incident non-vertebral fracture group versus the no fracture group (reference level: no incident fracture group) between pre and post HRQL measurements. The covariates included in the multiple regression analysis were group; baseline mini-OQLQ score; group by baseline mini-OQLQ score interaction; number of years between pre and post administration of the mini-OQLQ; age; baseline height; baseline weight; change in height (post-pre); prevalent vertebral and non-vertebral fracture status; number of prevalent vertebral and non-vertebral fractures; time spent exercising (hours/week); dietary calcium intake (g/day); baseline bone mineral density of the lumbar spine and femoral neck; medications such as bisphosphonates (etidronate or alendronate), estrogen, or others (calcitonin, fluoride or raloxifene); and co-morbidities (including heart attack; stroke; breast, ovarian, cervical, uterine and colon cancer and multiple myeloma; diabetes, epilepsy, arthritis, and thyroid disease). b (n) = sample size. c indicates a non significant differences between groups (the non-vertebral fracture group (II) versus the no fracture group (III)).